This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Concordia Healthcare Corp.
Drug Names(s): Alfuzosin, Xatral OD, Xatral XL
Description: UroXatral (Alfuzosin) is a selective antagonist of post-synaptic alpha1-adrenoreceptors. Alfuzosin selectively blocksalpha1-adrenergic receptors in the lower urinary tract. Blockade of theseadrenoreceptors can cause smooth muscle in the bladder neck and prostate torelax, resulting in an improvement in urine flow and a reduction in thesymptoms of BPH.
This 10 mg once-daily extended-release formulation was developed for Sanofi-Synthelabo by SkyePharma and involves SkyePharma's proprietary Geomatrix oral controlled-release drug delivery technology. SkyePharma earns low single digit royalties on net sales of Uroxatral.
Sanofi and Covis
In April 2013, Covis Pharma Sarl announced an agreement with Sanofi-Aventis to acquire full commercial rights for Nilandron (nilutamide), Plaquenil (hydroxychloroquine), Rilutek (riluzole), Uroxatral (alfuzosin hydrochloride), and Kayexalate (sodium polystyrene sulfate) in the United States. Sanofi will retain the existing rights for these products in countries outside the United States. Terms of the agreement have not been disclosed. Covis Pharma will promote these branded products through its US-based distributor, Covis Pharmaceuticals Inc. Sanofi will manufacture and supply the products for Covis Pharma. The agreement has received Hart-Scott-Rodino regulatory clearance in the...See full deal structure in Biomedtracker
Partners: Vectura Group Sanofi
Pink Sheet SkyePharma/Sanofi UroXatral "approvable"
Pink Sheet UroXatral launch
Pink Sheet Levitra, UroXatral QT prolongation
Additional information available to subscribers only: